Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis

Journal of Clinical Investigation

Volumn 100, Issue 8, 1997, Pages 2133-2137

  Franklin, Wilbur A ^a,d   Gazdar, Adi F ^b   Haney, Jerry ^a   Wistuba, Ignacia I ^b   La Rosa, Francisco G ^a   Kennedy, Tim ^c   Ritchey, Donald M ^a   Miller, York E ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c Lung Cancer Institute of Colorado   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Field cancerization; Lung neoplasms; Precancerous conditions; Smoking; Tumor suppressor genes

Indexed keywords

PROTEIN P53;

AGED; ARTICLE; BRONCHUS MUCOSA; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; MALE; POINT MUTATION; PRIORITY JOURNAL; STEM CELL; TRACHEOBRONCHIAL TREE; TUMOR SUPPRESSOR GENE;

EID: 0030772811     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119748     Document Type: Article

References (48)

1. Slaughter, D.P., H.W. Southwick, and W. Smejkal. 1953. "Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 6:963-968.
2. Mathisen, D.J., R.J. Jensik, L.P. Faber, and C.F. Kittle. 1984. Survival following resection for second and third primary lung cancers. J. Thorac. Cardiovasc. Surg. 88:502-510.
3. Ferguson, M.K., T.R. DeMeester, J. Deslauriers, A.G. Little, M. Piraux, and H. Golomb. 1985. Diagnosis and management of synchronous lung cancers. J. Thorac. Cardiovasc. Surg. 89:378-385.
4. Wu, S.C., Z.Q. Lin, C.W. Xu, K.S. Koo, O.L. Huang, and D.Q. Xie. 1987. Multiple primary lung cancers. Chest. 92:892-896.
5. Deschamps, C., P.C. Pairolero, V.F. Trastek, and W.S. Payne. 1990. Multiple primary lung cancers. Results of surgical treatment. J. Thorac. Cardiovasc. Surg. 99:769-777.
6. Ferguson, M.K. 1993. Synchronous primary lung cancers. Chest. 103: 398S-400S.
7. Antakli, T., R.F. Schaefer, J.E. Rutherford, and R.C. Read. 1995. Second primary lung cancer. Ann. Thorac. Surg. 59:863-866.
8. Martini, N., M.S. Bains, M.E. Burt, M.F. Zakowski, P. McCormack, V.W. Rusch, and R.J. Ginsberg. 1995. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 109: 120-129.
9. Pommier, R.F., J.T. Vetto, J.T. Lee, and K.M. Johnston. 1996. Synchronous non-small cell lung cancers. Am. J. Surg. 171:521-524.
10. Johnson, B.E., R.I. Linnoila, J.P. Williams, D.J. Venzon, P. Okunieff, G.B. Anderson, and G.E. Richardson. 1995. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J. Clin. Oncol. 13:101-111.
11. Thomas, P., and L. Rubinstein. 1990. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann. Thorac. Surg. 49:242-246.
12. Heyne, K.H., S.M. Lippman, J.J. Lee, J.S. Lee, and W.K. Hong. 1992. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J. Clin. Oncol. 10:1519-1524.
13. Johnson, B.E., D.C. Ihde, M.J. Matthews, P.A. Bunn, A. Zabell, R.W. Makuch, A. Johnston-Early, M.H. Cohen, E. Glatstein, and J.D. Minna. 1986. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. Am. J. Med. 80:1103-1110.
14. Sidransky, D., P. Frost. A. Von Eschenbach, R. Oyasu, A.C. Preisinger, and B. Vogelstein. 1992. Clonal origin bladder cancer. N. Engl. J. Med. 326:737-740.
15. Sozzi, G., M. Miozzo, U. Pastorino, S. Pilotti, R. Donghi, M. Giarola, L. De Gregorio, G. Manenti, P. Radice, F. Minoletti, et al. 1995. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 55:135-140.
16. Saccomanno, G., V.E. Archer, O. Auerbach, R.P. Saunders, and L.M. Brennan. 1974. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 33:256-270.
17. Hung, J., Y. Kishimoto, K. Sugio, A. Virmani, D.D. McIntire, J.D. Minna, and A.F. Gazdar. 1995. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (J. Am. Med. Assoc.). 273:558-563.
18. Soto, D., and S. Sukumar. 1992. Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl. 2:96-98.
19. Phelps R. M., B.E. Johnson, D.C. Ihde, A.F. Gazdar, D.P. Carbone, P.R. McClintock, R.I. Linnoila, M.J. Matthews, P.A. Bunn, Jr., D. Carney, et al. 1996. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. Suppl. 24:32-91.
20. Fearon, E.R., and B. Vogelstein. 1990. A genetic model for colorectal tumorigenesis. Cell. 61:759-767.
21. Knudson, A.G. 1993. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA. 90:10914-10921.
22. Dutrillaux, B. 1995. Pathways of chromosome alteration in human epithelial cancers. Adv. Cancer Res. 67:59-82.
23. Vogelstein, B., and K.W. Kinzler. 1993. The multistep nature of cancer. Trends Genet. 9:138-141.
24. Cho, K.R., and B. Vogelstein. 1992. Genetic alterations in the adenoma - carcinoma sequence. Cancer. 70:1727-1731.
25. Greenblatt, M.S., W.P. Bennett, M. Hollstein, and C.C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
26. Yuspa, S.H., and M.C. Poirier. 1988. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res. 50:25-70.
27. Strauss, B.S. 1991. The A 'rule' of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? Bioessays. 13:79-84.
28. Sundaresan, V., P. Ganly, P. Hasleton, R. Rudd, G. Sinha, N.M. Bleehen, and P. Rabbitts. 1992. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 7:1989-1997.
29. Sozzi, G., M. Miozzo, R. Donghi, S. Pilotti, C.T. Cariani, U. Pastorino, G. Della Porta, and M.A. Pierotti. 1992. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 52:6079-6082.
30. Chung, G.T., V. Sundaresan, P. Hasleton, R. Rudd, R. Taylor, and P.H. Rabbitts. 1996. Clonal evolution of lung tumors. Cancer Res. 56:1609-1614.
31. Chung, G.T., V. Sundaresan, P. Hasleton, R. Rudd, R. Taylor, and P.H. Rabbitts. 1995. Sequential molecular genetic changes in lung cancer development. Oncogene. 11:2591-2598.
32. Kishimoto. Y., K. Sugio, J.Y. Hung. A.K. Virmam, D.D. McIntire, J.D. Minna, and A.F. Gazdar. 1995. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl. Cancer Inst. (Bethesda). 87:1224-1229.
33. Mao, L., J.S. Lee, J.M. Kurie, Y.H. Fan, S.M. Lippman, J.J. Lee, J.Y. Ro, A. Broxson, R. Yu, R.C. Morice, et al. 1997. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89:857-862.
34. Fontanini, G., S. Vignati, D. Bigini, G.R. Merlo, A. Ribecchini, C.A. Angeletti, F. Basolo, R. Pingitore, and G. Bevilacqua. 1994. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol. 174:23-31.
35. Bennett, W.P., T.V. Colby, W.D. Travis, A. Borkowski, R.T. Jones, D.P. Lane, R.A. Metcalf, J.M. Samet, Y. Takeshima, and J.R. Gu. 1993. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 53:4817-4822.
36. Walker, C., G.R. Dixon, and M. Myskow. 1995. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression [letter]. J. Pathol. 176:319-320.
37. Rusch, V., D. Klimstra, I. Linkov, and E. Dmitrovsky. 1995. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 55:1365-1372.
38. Boers, J.E., G.P. ten Velde, and F.B. Thunnissen. 1996. p53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am. J. Respir. Crit. Care Med. 153:411-116.
39. Hartwell, L. 1992. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 71:543-546.
40. Levine, A.J., J. Momand, and C.A. Finlay. 1991. The p53 tumour suppressor gene. Nature (Lond.). 351:453-456.
41. Lane. D.P. 1992. Cancer. p53, guardian of the genome [news: comment]. Nature (Lond.). 358:15-16.
42. Wang, P., M. Reed, Y. Wang, G. Mayr, J.E. Stenger, M.E. Anderson, J.F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: structure, oligomerization and transformation. Mol. Cell. Biol. 14:5182-5191.
43. Sakamoto, H., M.S. Lewis, H. Kodama, E. Appella, and K. Sakaguchi. 1994. Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc. Natl. Acad. Sci. USA. 91: 8974-8978.
44. Milner, J., E.A. Medcalf, and A.C. Cook. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11:12-19.
45. Sturzbecher, H.W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J.R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene. 7:1513-1523.
46. Sheppard, D. 1994. Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am. J. Respir. Cell Mol. Biol. 11:1-6.
47. Herskowitz, I. 1987. Functional inactivation of genes by dominant negative mutations. Nature (Lond). 329:219-222.
48. Frebourg, T., M. Sadelain, Y.S. Ng, J. Kassel, and S.H. Friend. 1994. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. 54:878-881.